WO2019245513A3 - A combination comprising fingolimod and amantadine - Google Patents

A combination comprising fingolimod and amantadine Download PDF

Info

Publication number
WO2019245513A3
WO2019245513A3 PCT/TR2019/050477 TR2019050477W WO2019245513A3 WO 2019245513 A3 WO2019245513 A3 WO 2019245513A3 TR 2019050477 W TR2019050477 W TR 2019050477W WO 2019245513 A3 WO2019245513 A3 WO 2019245513A3
Authority
WO
WIPO (PCT)
Prior art keywords
fingolimod
amantadine
combination
treatment
pharmaceutically acceptable
Prior art date
Application number
PCT/TR2019/050477
Other languages
French (fr)
Other versions
WO2019245513A2 (en
Inventor
Ali Turkyilmaz
Merve PEKER
Emine TUNCAY
Erkin Ozturk
Muge ULUSOY BOZYEL
Yavuz Dedeoglu
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority to EP19823241.5A priority Critical patent/EP3810110A4/en
Publication of WO2019245513A2 publication Critical patent/WO2019245513A2/en
Publication of WO2019245513A3 publication Critical patent/WO2019245513A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a pharmaceutical combination comprising fingolimod or a pharmaceutically acceptable salt thereof and amantadine or a pharmaceutically acceptable salt thereof for use in the treatment of multiple sclerosis in human, preferably in the prevention or the treatment of fatigue symptom of multiple sclerosis disease.
PCT/TR2019/050477 2018-06-21 2019-06-20 A combination comprising fingolimod and amantadine WO2019245513A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP19823241.5A EP3810110A4 (en) 2018-06-21 2019-06-20 A combination comprising fingolimod and amantadine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201808819 2018-06-21
TR2018/08819 2018-06-21

Publications (2)

Publication Number Publication Date
WO2019245513A2 WO2019245513A2 (en) 2019-12-26
WO2019245513A3 true WO2019245513A3 (en) 2020-03-19

Family

ID=68983747

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2019/050477 WO2019245513A2 (en) 2018-06-21 2019-06-20 A combination comprising fingolimod and amantadine

Country Status (2)

Country Link
EP (1) EP3810110A4 (en)
WO (1) WO2019245513A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016064997A1 (en) * 2014-10-22 2016-04-28 The Regents Of The University Of California Compositions and methods for treating fatigue and depression
WO2016073510A1 (en) * 2014-11-04 2016-05-12 Adamas Pharmaceuticals, Inc. Methods of administering amantadine compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014004420A (en) * 2011-10-12 2014-07-09 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016064997A1 (en) * 2014-10-22 2016-04-28 The Regents Of The University Of California Compositions and methods for treating fatigue and depression
WO2016073510A1 (en) * 2014-11-04 2016-05-12 Adamas Pharmaceuticals, Inc. Methods of administering amantadine compositions

Also Published As

Publication number Publication date
EP3810110A2 (en) 2021-04-28
EP3810110A4 (en) 2022-03-16
WO2019245513A2 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
MX2019009443A (en) Methods of treating influenza.
MX2019012884A (en) Combination therapy.
EP4272818A3 (en) Thrombolytic agent for the treatment of thromboembolism
MX2018013003A (en) Oligonucleotides to treat eye disease.
MX2021000071A (en) Use of pridopidine to improve cognitive function and for treating alzheimer's disease.
MX2019011117A (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof.
MX2021004110A (en) Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n' -(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl] ethane-1,2-diamine.
MX2024010140A (en) Novel methods.
MX2016010179A (en) Donepezil compositions and method of treating alzheimer's disease.
MX2022002196A (en) Niclosamide delayed-release composition and antiviral use thereof.
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
RS65630B1 (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease
WO2016040169A3 (en) Mucolytic agents for use in tretaing pulmonary sarcoidosis
MX2021011269A (en) Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EP3590338A3 (en) Medical treatments based on anamorelin
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2021015338A (en) Composition comprising pridopidine and analog thereof for treating huntington disease and symptoms thereof.
WO2019245513A3 (en) A combination comprising fingolimod and amantadine
MX2020005310A (en) Combination product comprising dicycloplatin and preparation method and use thereof.
MX2020003427A (en) Therapeutic agents for neurodegenerative diseases.
WO2020117151A3 (en) A combination comprising fingolimod and modafinil
MX2020001217A (en) Methods of treating symptoms of gastroparesis using velusetrag.
EP3669880A4 (en) USE OF miR-18b FOR PREVENTION, TREATMENT, OR DIAGNOSIS OF MUSCLE DISEASE AND NEUROMUSCULAR DISEASE
EP4335508A3 (en) (+)-azasetron for use in the treatment of ear disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19823241

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2019823241

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2019823241

Country of ref document: EP

Effective date: 20210121

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19823241

Country of ref document: EP

Kind code of ref document: A2